Zevra Therapeutics (NASDAQ: ZVRA) is a biopharmaceutical company that develops treatments for rare diseases. Its work focuses on conditions such as idiopathic hypersomnia and stimulant use disorder. In the competitive biopharma industry, a company's financial efficiency is a key indicator of its potential. Zevra's performance is often measured against its closest competitors.
A company's ability to create value is measured by comparing two key metrics. Return on Invested Capital (ROIC) shows how well a company uses its money to generate profits. A higher ROIC suggests more efficient use of capital. This is compared against the Weighted Average Cost of Capital (WACC).
WACC represents the average cost a company pays for its financing from investors and lenders. It is the minimum return required to satisfy them. If a company's ROIC is higher than its WACC, it is creating value. If the ROIC is lower, it is destroying value.
Zevra's current ROIC is -19.57%, which is below its WACC of 8.71%. This results in an ROIC to WACC ratio of -2.25. This negative return is common for biopharma companies that invest heavily in research and development before their products generate revenue.
Compared to its peers, Zevra shows greater capital efficiency. Competitors like Inhibikase Therapeutics and Inozyme Pharma have ROIC to WACC ratios of -3.79 and -5.33, respectively. Although Zevra's ratio is negative, it is the highest in its peer group, indicating it destroys value at a slower rate.
